Cel-Sci Corporation (NYSEAMERICAN:CVM) Short Interest Up 172.4% in July

Cel-Sci Corporation (NYSEAMERICAN:CVM) saw a significant growth in short interest in the month of July. As of July 15th, there was short interest totaling 718,008 shares, a growth of 172.4% from the June 30th total of 263,542 shares. Currently, 4.6% of the company’s shares are short sold. Based on an average daily volume of 399,680 shares, the short-interest ratio is presently 1.8 days.

Cel-Sci Price Performance

Shares of NYSEAMERICAN CVM remained flat at $1.18 during mid-day trading on Monday. The stock had a trading volume of 146,707 shares, compared to its average volume of 274,073. The company has a quick ratio of 0.54, a current ratio of 0.60 and a debt-to-equity ratio of 0.64. Cel-Sci has a twelve month low of $0.89 and a twelve month high of $13.48. The firm has a market cap of $20.63 million, a PE ratio of -0.12 and a beta of 0.64. The business’s 50-day moving average is $1.26 and its 200 day moving average is $3.12.

Cel-Sci (NYSEAMERICAN:CVM) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.67) earnings per share for the quarter.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. US Bancorp DE purchased a new stake in shares of Cel-Sci in the 3rd quarter valued at approximately $80,000. HighTower Advisors LLC acquired a new position in Cel-Sci in the 4th quarter worth approximately $53,000. HRT Financial LP purchased a new position in Cel-Sci during the 4th quarter worth approximately $60,000. XTX Topco Ltd purchased a new position in Cel-Sci during the 4th quarter worth approximately $66,000. Finally, Renaissance Technologies LLC acquired a new stake in Cel-Sci during the 4th quarter valued at $81,000. 12.08% of the stock is owned by hedge funds and other institutional investors.

Cel-Sci Company Profile

CEL-SCI Corporation is a biotechnology company focused on the development of immunotherapy products to treat cancer and infectious diseases. Founded in 1983 and headquartered in Vienna, Virginia, the company applies its proprietary LEAPS® (Ligand Epitope Antigen Presentation System) and Multikine® immunotherapy platforms to stimulate the body’s immune response against disease. CEL-SCI operates as a clinical-stage enterprise, working to translate immunological insights into therapeutic candidates.

The company’s lead product candidate, Multikine (leukineferon), is an investigational immunotherapy designed to enhance the immune system’s ability to attack head and neck cancer cells.